Genomenon Partners with Three Rare Disease Foundations to Advance Precision Drug Development
ANN ARBOR, Mich., Nov. 29, 2022 /PRNewswire-PRWeb/ -- Genomenon Inc., an AI-driven genomics company, announced a partnership with COMBINEDBrain, SynGAP Research Fund, and SLC-6A1 Connect. Genomenon will collaborate with the foundations and their pharma partners, delivering comprehensive genomic data on their diseases of focus with the goal of accelerating the development of precision drugs to treat rare neurodevelopmental disorders.
- Genomenon will collaborate with the foundations and their pharma partners, delivering comprehensive genomic data on their diseases of focus with the goal of accelerating the development of precision drugs to treat rare neurodevelopmental disorders.
- Genomenon is partnering with COMBINEDBrain, SynGAP, and SLC-6A1 Connect to provide that essential information to ensure the best chance of success.
- Genomenon is an AI-driven genomics company focused on making genomic information actionable for patients with rare genetic diseases and cancer.
- Keeping pace with the ever-evolving body of knowledge within genomics, Genomenon connects current research with patient DNA to accelerate clinical decision-making and pharmaceutical drug discovery.